Summary & Overview

CPT 0258U: Mind.Px Psoriasis NGS Gene Expression Assay

CPT code 0258U designates Mind.Px, a proprietary next-generation sequencing (NGS) gene expression assay produced by Mindera Corporation for use on psoriasis skin specimens collected with a proprietary patch. As a PLA code tied to a single manufacturer and test, it captures a targeted 50–100 gene expression profile and uses algorithmic interpretation to inform medication selection for psoriasis. Nationally, PLA codes like 0258U matter because they codify unique, commercially available molecular diagnostics and enable standardized billing and reporting for precision medicine tools.

Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical purpose and service delivery, payer coverage context, typical sites of service, and common billing modifiers associated with laboratory services. The publication summarizes benchmark considerations for proprietary molecular assays, highlights policy and coding implications for single-source tests, and presents clinical context for use in treatment selection for psoriasis.

This report is intended for revenue cycle professionals, laboratory directors, clinicians ordering molecular diagnostics, and policy analysts seeking a national view of how a PLA-coded psoriasis gene expression test is described and classified for billing and coverage discussion.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0258UCPTproprietary laboratory analysismolecular diagnosticspsoriasisNGS gene expressionprecision medicinelaboratory billingPLA code

Billing Code Overview

CPT code 0258U is a Proprietary Laboratory Analyses (PLA) code for the Mind.Px test manufactured by Mindera Corporation. The assay is performed on a psoriasis skin specimen collected with a proprietary patch that captures RNA from the lesion. The test uses next-generation sequencing (NGS) to evaluate gene expression across a targeted panel of 50 to 100 genes and applies an algorithmic analysis to aid in selecting appropriate medication for psoriasis treatment.

Service type: Laboratory — molecular diagnostic, proprietary gene expression assay

Typical site of service: Clinical laboratory or reference lab

Clinical & Coding Specifications

Clinical Context

A 38-year-old patient with moderate-to-severe plaque psoriasis presents to a dermatology clinic after inadequate response to first-line topical therapies and phototherapy. The dermatologist evaluates the active lesion and determines that molecular profiling of the lesional skin may help guide systemic or biologic therapy selection. A proprietary collection patch designed to capture RNA from the psoriasis lesion is applied to the affected skin in clinic; the patch is removed per manufacturer instructions and the specimen is sent to the manufacturer-specific laboratory (Mindera Corporation) for the Mind.Px test. The laboratory performs next-generation sequencing (NGS)–based gene expression analysis of a focused panel (50–100 genes) and algorithmic interpretation to identify medication-response signatures. Results are returned to the ordering dermatologist, who integrates the report with clinical history, prior treatment response, and comorbidities to inform selection of a systemic agent or biologic. Typical site of service is an outpatient dermatology clinic or ambulatory surgical center for specimen collection; laboratory processing occurs at the vendor’s central lab. Service type: Proprietary Laboratory Analyses (PLA) molecular diagnostic test using NGS-based gene expression profiling on a psoriasis skin specimen collected with a proprietary patch.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard reporting	Use when no special circumstances apply.

CPT 0522U: Tissue-Specific Markers for Early Diagnosis of Sjögren’s Disease

cpt-0226u-tru-immune-neutralizing-antibody-assay

CPT 0226U: Tru–Immune Neutralizing Antibody Assay

cpt-0321u-bridge-urinary-tract-infection-detection-resistance-test

CPT 0321U: Urinary Tract Infection Detection and Resistance Test

cpt-0571u-liquidhallmark-ctdna-ctrna-ngs-80-genes

CPT 0571U: LiquidHALLMARK® ctDNA and ctRNA NGS Assay

cpt-0213u-whole-genome-comparator-analysis

CPT 0213U: Whole Genome and Mitochondrial Comparator Analysis

cpt-0350u-pharmacogenomic-ngs-27-gene-panel-rightmed

CPT 0350U: Pharmacogenomic NGS 27-Gene Panel (RightMed® Gene Report)

cpt-0378u-ucgsl-rfc1-repeat-expansion-test-canvas

CPT 0378U: UCGSL RFC1 Repeat Expansion Test for CANVAS

cpt-0590u-biotia-id-urine-ngs-assay-uropathogen-detection

CPT 0590U: BIOTIA ID™ Urine NGS Assay for Uropathogen Detection

cpt-0061u-transcutaneous-multispectral-tissue-oxygenation-imaging

CPT 0061U: Transcutaneous Multispectral Tissue Oxygenation Imaging

cpt-0216u-ataxia-repeat-expansion-sequence-analysis

CPT 0216U: Ataxia Repeat Expansion and Sequence Analysis

Showing 1–10 of 557

Taxonomy Code	Specialty	Notes
207N00000X	Dermatology	Ordering clinicians who evaluate psoriasis and request lesional molecular testing.
207L00000X	Dermatopathology	Pathologists who may interpret skin sampling and correlate molecular results with histopathology.
207RN0001X	Medical Oncology	Specialists who may use molecular profiling results when systemic immunomodulatory or biologic therapies overlap with oncology agents or in complex cases.
363L00000X	Laboratory Director	Clinical laboratory directors overseeing processing and CLIA compliance at the reference lab.
208000000X	Family Medicine	Primary care physicians who may order or coordinate molecular testing in collaboration with dermatology for systemic therapy selection.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L40.0`	Psoriasis vulgaris	Most common form of plaque psoriasis; direct indication for lesional molecular profiling to guide systemic therapy selection.
`L40.9`	Psoriasis, unspecified	Used when psoriasis is diagnosed but specific subtype not documented; still clinically relevant for testing to inform treatment.
`L40.8`	Other psoriasis	Includes less common subtypes where molecular profiling may assist in therapeutic decisions.
`L40.5`	Arthropathic psoriasis	Psoriasis with joint involvement; molecular profiling may influence systemic therapy selection encompassing joint disease.
`L40.1`	Generalized pustular psoriasis	Severe subtype where targeted systemic agents may be guided by molecular markers in select clinical contexts.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0258U`	Mind.Px: NGS gene expression profiling (50–100 genes) with algorithmic analysis to aid medication selection for psoriasis (PLA)	Primary PLA code to report the vendor-specific test performed on a psoriasis lesional patch specimen.
`11100`	Biopsy of skin, subcutaneous tissue and/or mucous membrane (single lesion)	May be performed if a traditional diagnostic skin biopsy is needed instead of, or in addition to, lesional RNA patch collection for histology.
`99000`	Services provided in the office at times other than regularly scheduled office hours, or urgent services — typically use varies by payer	May apply for after-hours specimen collection or urgent procedural services related to collection when payer allows.
`88172`	Cytopathology, immunocytochemistry per single antigen stain	May be used in parallel when ancillary cytologic or immunostain evaluation of a specimen is performed by a pathology lab.
`80500`	Laboratory test, multiple assays or panels; molecular pathology procedures (representative code for molecular testing workflow)	Represents molecular testing framework; used in workflows where additional molecular tests or panels are run in conjunction with a PLA, subject to payer policy on PLA bundling.

OpenPayer